What is the safety and clinical effectiveness, acceptability and cost effectiveness of flexible delivery of natalizumab (Tysabri (Registered Trademark)) by ambulatory care nurses for people with multiple sclerosis?

Trial Profile

What is the safety and clinical effectiveness, acceptability and cost effectiveness of flexible delivery of natalizumab (Tysabri (Registered Trademark)) by ambulatory care nurses for people with multiple sclerosis?

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top